Heart valve specialist, Edwards Lifesciences Corporation, has agreed to acquire privately held CardiAQ™ Valve Technologies, Inc., developer of a transcatheter mitral valve (TMV) replacement system.
Californian outfit, CardiAQ has developed a proprietary transcatheter mitral valve implant that can be delivered through multiple delivery systems. Through its unique anchoring mechanism that engages and utilizes the patient’s native mitral valve anatomy, physicians will be able to implant a new mitral valve within a beating heart without circulatory support, thus avoiding open-heart surgery. OrbiMed led the series B financing and is CardiAQ’s largest shareholder. Other venture investors include Broadview, Advent and Versant.
Having seen a first implant of its TMV implant as recently as last month, CardiAQ has received a U.S. FDA Investigational Device Exemption (IDE) approval to conduct an early feasibility study of up to 20 patients, and also plans to initiate a CE Mark study in Europe. For now though, the CardiAQ and FORTIS valve systems are not approved for sale in any country.
The purchase price is up to $400 million, including $350 million in cash at closing, and the remainder payable upon achievement of a European regulatory milestone. The transaction remains subject to customary closing conditions. Unsurprisingly Edwards says it expects that this acquisition will be slightly dilutive to 2015 earnings per share.
for Edwards Lifesciences
“Edwards’ primary strategy is to create valuable therapies that transform patient care. We believe the acquisition and integration of CardiAQ will advance our development of a transformational therapy for patients with mitral valve disease who aren’t well-served today,” said Michael A. Mussallem, Edwards’ chairman and CEO. “While still early in the development of this therapy, the progress of the team of employees and clinicians working on our FORTIS mitral replacement system has reinforced our confidence in a catheter-based approach. We believe the experiences and technologies of FORTIS and CardiAQ are complementary and that this combination will enable important advancements for patients.”
“CardiAQ is proud of our pioneering efforts in the early development of this transcatheter mitral valve therapy conceived by cardiac surgeon Arshad Quadri, M.D. We believe our technology, which incorporates multiple delivery approaches with a single valve, shows great promise for patients,” said Rob Michiels, chief executive officer of CardiAQ.
“We look forward to joining Edwards, whose experience and leadership as a developer of breakthrough therapies for heart valve disease will advance our work,” said J. Brent Ratz, co-founder, president and chief operating officer of CardiAQ.
Source: Edwards Lifesciences Corporation